Freezing cancer cells: could cryoablation boost immunotherapy?

NCT ID NCT04150939

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests whether adding cryoablation—a procedure that freezes and kills cancer cells—can improve the effectiveness of standard immunotherapy in people with metastatic cancer. Fifteen participants will receive both treatments, and researchers will measure how many patients see their tumors shrink or disappear. The goal is to see if this combination can better control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cryoablation (freezing tumors) plus standard immunotherapy
What this could lead to: If it works, this could point toward a way to boost the effectiveness of immunotherapy for people with metastatic cancer.
What could go wrong: This is a very small early-phase trial with only 15 participants, so results may not apply broadly. The added procedure carries risks like infection or damage to nearby tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MALIGNANT NEOPLASM

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.